Ignite Creation Date:
2024-05-06 @ 5:51 PM
Last Modification Date:
2024-10-26 @ 2:37 PM
Study NCT ID:
NCT05456880
Status:
RECRUITING
Last Update Posted:
2024-06-26
First Post:
2022-06-23
Brief Title:
BEACON A Study Evaluating the Safety and Efficacy of BEAM-101 in Patients With Severe Sickle Cell Disease
Sponsor:
Beam Therapeutics Inc
Organization:
Beam Therapeutics Inc
Study Overview
Official Title:
A Phase 12 Study Evaluating the Safety and Efficacy of a Single Dose of Autologous CD34 Base Edited Hematopoietic Stem Cells BEAM-101 in Patients With Sickle Cell Disease and Severe Vaso-Occlusive Crises Beacon Trial
Status:
RECRUITING
Status Verified Date:
2024-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
BEACON
Brief Summary:
This is an open-label single-arm multicenter Phase 12 study evaluating the safety and efficacy of the administration of autologous base edited CD34 HSPCs BEAM-101 in patients with severe SCD
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None